InnoCentive Theoretical IP Transfer Challenge: Selective Conjugation Method for Small Format Antibodies

Closing Date: 15/10/2022

Innovation challenge seeking innovative concepts for chemical conjugation methods that are applicable to small format antibodies, specifically an efficient method of linking either a cytotoxic drug and/or a trackable probe to small format antibodies.

InnoCentive is a global innovation hub, operated by Wazoku, that hosts a range of innovation challenges for the wider benefit of humankind. Commercial, governmental, public sector, non-profit and humanitarian organisations (“Seekers”) can engage with the InnoCentive community to solicit solutions to innovation or development challenges by offering financial awards.

Individuals, groups and organisations can register as “Solvers” on InnoCentive to take part in the various innovation challenges.

This InnoCentive Theoretical IP Transfer Challenge – Selective Conjugation Method for Small Format Antibodies – has been put forward by Debiopharm, the Swiss pharmaceutical company, to seek innovative concepts for chemical conjugation methods that are applicable to small format antibodies.

Small format antibodies are significantly smaller and have a lower molecular weight than typical monoclonal antibodies. They eliminate non-specific binding with Fc receptors on cells, while also gaining the ability to penetrate tissues more efficiently due to their compact size.

To take advantage of the beneficial properties of small format antibodies, the Challenge is seeking concepts for an efficient method for linking either a cytotoxic drug and/or a trackable probe to small format antibodies.

Funding body Debiopharm
Maximum value 40,000 USD
Reference ID S24264
Category Biotechnology and Biology
Engineering and Physical Sciences
Medical Research
Fund or call Fund